

# News Release

February 2, 2022

## **Regulatory Approval of Cariprazine (MP-214) for Bipolar Disorder in Singapore**

Mitsubishi Tanabe Pharma Corporation (MTPC, Head Office: Chuo-ku, Osaka, Japan; President & Representative Director: Hiroaki Ueno) announced that MTPC's subsidiary, Mitsubishi Tanabe Pharma Singapore Pte. Ltd. obtained the regulatory approval of cariprazine (generic name; development code: MP-214; dopamine D3/D2 receptor partial agonist; trademark in Singapore: SYMVENU®) for the treatment of bipolar disorder in Singapore from the Singaporean Health Sciences Authority on January 25.

Bipolar disorder is a mental disorder, and the exact cause is unknown. It is a disorder in which a manic state, in which patients' mood swings, and a depressive state, in which patients feel heavy and depressed, are repeated alternately. When patients are depressed, they continue to feel depressed and may lose appetite or ability to move. In contrast, manic episodes make patients feel more active, energized and/or agitated, with a decreased need for sleep. Symptoms vary depending on the circumstances. The number of patients in Singapore is estimated to be approximately 81 thousand.

MTPC Group is committed to seeking early approval of the indication for bipolar disorder not only in Singapore but also in other countries in MTPC's territory and will continue to promptly respond to regulatory authorities in each country.

MTPC Group aims to deliver cariprazine to patients with bipolar disorder and increase quality of life.

**Mitsubishi Tanabe Pharma Corporation**  
**Communication Crossroads Department**  
Media contacts: TEL: +81 6 6205 5119

A member of Mitsubishi Chemical Holdings Group.

**KAITEKI Value for Tomorrow**  
Mitsubishi Chemical Holdings Group

### ■ **About Cariprazine (MP-214)**

Mitsubishi Tanabe Pharma Corporation (MTPC) has been developed Cariprazine, which is licensed from Gedeon Richter Plc. in Hungary, in some Asian countries. Cariprazine is an oral atypical antipsychotic approved for the treatment of schizophrenia in MTPC's territory, in Singapore and Thailand in July 2019, in Malaysia in August 2020, and in Indonesia in July 2021. While the mechanism of action of cariprazine is unknown, the efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D<sub>2</sub> and serotonin 5-HT<sub>1A</sub> receptors and antagonist activity at serotonin 5-HT<sub>2A</sub> receptors. Pharmacodynamic studies with cariprazine have shown that it acts as a partial agonist with high binding affinity at dopamine D<sub>3</sub>, dopamine D<sub>2</sub>, and serotonin 5-HT<sub>1A</sub> receptors.

### ■ **About Mitsubishi Tanabe Pharma Singapore Pte. Ltd.**

Mitsubishi Tanabe Pharma Singapore Pte. Ltd. was founded as a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Singapore in 2016. As a company in charge of supervising the ASEAN region, where the economies and pharmaceutical markets have been rapidly growing, the company carries out its operations, including development, in order to promptly provide patients in ASEAN countries with our innovative pharmaceutical products that can satisfy local unmet medical needs. Future Symvenu<sup>®</sup> will be promoted by itself.